RESUMEN
A lead generation and optimization program delivered the highly selective and potent CatC inhibitor 10 as an in vivo tool compound and potential development candidate. Structural studies were undertaken to generate SAR understanding.
Asunto(s)
Catepsina C/antagonistas & inhibidores , Inhibidores de Proteasas/síntesis química , Inhibidores de Proteasas/farmacología , Humanos , Indicadores y Reactivos , Modelos Moleculares , Conformación Molecular , Proteínas Recombinantes/química , Espectrometría de Fluorescencia , Relación Estructura-Actividad , Especificidad por Sustrato , Difracción de Rayos XRESUMEN
The optimization of a new series of muscarinic M(3) antagonists is described, leading to the identification of AZD9164 which was progressed into the clinic for evaluation of its potential as a treatment for COPD.
Asunto(s)
Antagonistas Muscarínicos/química , Piperidinas/química , Quinuclidinas/química , Receptor Muscarínico M3/agonistas , Proteínas Sanguíneas/metabolismo , Evaluación Preclínica de Medicamentos , Humanos , Antagonistas Muscarínicos/farmacología , Antagonistas Muscarínicos/uso terapéutico , Piperidinas/farmacología , Piperidinas/uso terapéutico , Unión Proteica , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Quinuclidinas/farmacología , Quinuclidinas/uso terapéutico , Receptor Muscarínico M3/metabolismo , Relación Estructura-ActividadRESUMEN
A novel series of biaryl phenoxyacetic acids was discovered as potent, selective antagonists of the chemoattractant receptor-homologous expressed on Th2 lymphocytes receptor (CRTh2 or DP2). A hit compound 4 was discovered from high throughput screening. Modulation of multiple aryl substituents afforded both agonists and antagonists, with small changes often reversing the mode of action. Understanding the complex SAR allowed design of potent antagonists such as potential candidate 34.
Asunto(s)
Acetatos/síntesis química , Receptores Inmunológicos/agonistas , Receptores Inmunológicos/antagonistas & inhibidores , Receptores de Prostaglandina/agonistas , Receptores de Prostaglandina/antagonistas & inhibidores , Acetatos/química , Acetatos/farmacología , Animales , Humanos , Concentración 50 Inhibidora , Estructura Molecular , Ratas , Relación Estructura-ActividadRESUMEN
By careful analysis of experimental X-ray ligand crystallographic protein data across several inhibitor series we have discovered a novel, potent and selective series of iNOS inhibitors exemplified by compound 8.
Asunto(s)
Inhibidores Enzimáticos/química , Isoxazoles/química , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Piridinas/química , Animales , Sitios de Unión , Simulación por Computador , Cristalografía por Rayos X , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacología , Humanos , Isoxazoles/síntesis química , Isoxazoles/farmacología , Ratones , Microsomas Hepáticos/metabolismo , Óxido Nítrico Sintasa de Tipo II/metabolismo , Estructura Terciaria de Proteína , Piridinas/farmacología , RatasRESUMEN
4-Methylaminopyridine (4-MAP) (5) is a potent but nonselective nitric oxide synthase (NOS) inhibitor. While simple N-methylation in this series results in poor activity, more elaborate N-substitution such as with 4-piperidine carbamate or amide results in potent and selective inducible NOS inhibition. Evidently, a flipping of the pyridine ring between these new inhibitors allows the piperidine to interact with different residues and confer excellent selectivity.
